STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma.
- Author:
Sung Hoon JUNG
1
;
Seo Yeon AHN
;
Hyun Woo CHOI
;
Myung Geun SHIN
;
Seung Shin LEE
;
Deok Hwan YANG
;
Jae Sook AHN
;
Yeo Kyeoung KIM
;
Hyeoung Joon KIM
;
Je Jung LEE
Author Information
- Publication Type:Original Article
- Keywords: STAT3; Multiple myeloma; Prognosis
- MeSH: Adult*; C-Reactive Protein; Calcium; Diagnosis; Disease-Free Survival; Humans; Multiple Myeloma*; Multivariate Analysis; Prognosis; STAT3 Transcription Factor; Stem Cell Transplantation
- From:Blood Research 2017;52(4):293-299
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) is not only a key signaling molecule in the regulation of growth but is also involved in malignant transformation. We investigated the prognostic significance of STAT3 expression in 94 non-elderly adult patients (aged 38 to 65 yr) with newly diagnosed multiple myeloma (MM). METHODS: Tumor cell-specific phosphotyrosine-STAT3 (PY-STAT3) expression at the time of diagnosis was evaluated with dual immunohistochemical (IHC) staining for PY-STAT3 and CD138. RESULTS: PY-STAT3 positivity was detected in 10 patients (10.6%), including three who showed strong expression. PY-STAT3-positive patients had higher serum C-reactive protein and calcium levels at diagnosis than did PY-STAT3-negative patients. PY-STAT3 positivity had predictive value for poor progression-free survival (PFS; P=0.001) and overall survival (OS; P=0.003). Among the 60 patients who received frontline autologous stem cell transplantation, PY-STAT3-positive patients had poorer PFS than did PY-STAT3-negative patients (4.2 vs. 19.2 mo, respectively; P=0.013). Multivariate analysis identified PY-STAT3 expression as an independent prognostic factor for PFS (relative risk [RR]=2.706, P=0.014) and OS (RR=3.091, P=0.044). CONCLUSION: These data show that PY-STAT3 positivity, as determined using dual IHC, is a marker of poor prognosis in non-elderly adult patients with MM.
